Effect of TNFα production inhibitors BRL 61063 and pentoxifylline on the response of rats to poly I:C

Kaplan, Johanne; Herzyk, Danuta J.; Ruggieri, Elizabeth V.; Bartus, Joan O'Leary; Esser, Klaus; Bugelski, Peter J.

doi:10.1016/0300-483x(94)02922-h

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1997

2010

Publication Types

Select...

Article4

Book1

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 9 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, the available literature points to the usefulness of agents such as flavonoids (Nagai et al, 1995; Wang et al, 2006; Liu et al, 2008), macrolides (Kido et al, 2007; Miyamoto et al, 2008), pentoxifylline (Kaplan et al, 1995), thiazolidinediones (Boris et al, 2007), and even antiviral drugs or vaccines.…”

mentioning

confidence: 99%

Multiple pathways in prevention of immune-mediated brain disorders: Implications for the prevention of autism

Fatemi

2009

Journal of Neuroimmunology

View full text Add to dashboard Cite

mentioning

confidence: 99%

Multiple pathways in prevention of immune-mediated brain disorders: Implications for the prevention of autism

Fatemi

2009

Journal of Neuroimmunology

View full text Add to dashboard Cite

Inhibition of Cyclic Nucleotide Phosphodiesterases by Methylxanthines and Related Compounds

Francis

Sekhar

et al. 2010

Handbook of Experimental Pharmacology

View full text Add to dashboard Cite

Naturally occurring methylxanthines were the first inhibitors of cyclic nucleotide (cN) phosphodiesterases (PDEs) to be discovered. To improve potency and specificity for inhibition of various PDEs in research and for treatment of diseases, thousands of compounds with related structures have now been synthesized. All known PDE inhibitors contain one or more rings that mimic the purine in the cN substrate and directly compete with cN for access to the catalytic site; this review focuses on inhibitors that contain a nucleus that is closely related to the xanthine ring of theophylline and caffeine and the purine ring of cNs. The specificity and potency of these compounds for blocking PDE action have been improved by appending groups at positions on the rings as well as by modification of the number and distribution of nitrogens and carbons in those rings. Several of these inhibitors are highly selective for particular PDEs; potent and largely selective PDE5 inhibitors are used clinically for treatment of erectile dysfunction [sildenafil (Viagra™), tadalafil (Cialis™) and vardenafil (Levitra™)] and pulmonary hypertension [sildenafil (Revatio™) and tadalafil (Adenocirca)]. Related compounds target other PDEs and show therapeutic promise for a number of maladies.

show abstract

Reversal of P-glycoprotein mediated vincristine resistance of L1210/VCR cells by analogues of pentoxifylline

Kupsáková

Rybar

Dočolomanský

et al. 2004

European Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

Effect of TNFα production inhibitors BRL 61063 and pentoxifylline on the response of rats to poly I:C

Cited by 9 publications

References 25 publications

Multiple pathways in prevention of immune-mediated brain disorders: Implications for the prevention of autism

Multiple pathways in prevention of immune-mediated brain disorders: Implications for the prevention of autism

Inhibition of Cyclic Nucleotide Phosphodiesterases by Methylxanthines and Related Compounds

Reversal of P-glycoprotein mediated vincristine resistance of L1210/VCR cells by analogues of pentoxifylline

Contact Info

Product

Resources

About